• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

["尖端扭转型室速" 及抗心律失常药物诱发的折返]

["Torsades de pointe" and reentry induced by anti-arrhythmia agents].

作者信息

Brochier M, Fauchier J P

出版信息

Arch Mal Coeur Vaiss. 1978 Apr;71(4):477-88.

PMID:78692
Abstract

Some anti-arrhythmic agents which have a stabilising effect on the membrane, particularly those belonging to Group I of Vaughan William's classification, are likely to cause rythmic disturbances by a re-entry phenomenon (atrial flutter 1/1, premature ventricular contractions, ventricular tachycardia, "torsades de pointe", even fatal ventricular fibrillation). The quinidines have been the most often condemned due to their effect on the action potential and on the speed of conduction. The fact that these re-entry phenomena are more frequent at therapeutic doses than at high or toxic doses suggests an individual susceptibility and the interaction of various predisposing factors: renal insufficiency, potassium depletion, pre-existing conduction disturbances, potentialsing drugs. In order to prevent these incidents it is advisable not to prescribe such anti-arrhythmic agents for susceptible patients, to control individual tolerance and to watch for the first ECG signs of conduction disturbances or of re-entry, such as premature contraction with fixed coupling. Treatment consists in an electrosystolic stimulus and the possible administration of potassium and bretylium.

摘要

一些对细胞膜有稳定作用的抗心律失常药物,特别是那些属于 Vaughan William 分类法第一类的药物,可能会通过折返现象导致节律紊乱(心房扑动1/1、室性早搏、室性心动过速、“尖端扭转型室速”,甚至致命的心室颤动)。奎尼丁因其对动作电位和传导速度的影响而最常受到谴责。这些折返现象在治疗剂量时比高剂量或中毒剂量时更频繁,这一事实表明存在个体易感性以及各种易感因素的相互作用:肾功能不全、钾缺乏、既往存在的传导障碍、潜在的药物。为了预防这些事件,建议不要给易感患者开此类抗心律失常药物,要控制个体耐受性,并留意传导障碍或折返的首次心电图迹象,如固定联律的早搏。治疗包括电收缩刺激以及可能给予钾和溴苄铵。

相似文献

1
["Torsades de pointe" and reentry induced by anti-arrhythmia agents].["尖端扭转型室速" 及抗心律失常药物诱发的折返]
Arch Mal Coeur Vaiss. 1978 Apr;71(4):477-88.
2
Drug-induced torsade de pointes.药物性尖端扭转型室性心动过速
Clin Pharm. 1985 Nov-Dec;4(6):675-90.
3
[Current anti-arrhythmic treatments and drugs].[当前的抗心律失常治疗方法与药物]
Coeur Med Interne. 1973 Jan-Mar;12(1):129-44.
4
[Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis].[伴有 1/1 房室传导的心房扑动与胺碘酮。从病理生理学到诊断]
Arch Mal Coeur Vaiss. 2002 Dec;95(12):1181-7.
5
[Harmful interactions of amiodarone and class I anti-arrhythmia agents].[胺碘酮与I类抗心律失常药物的有害相互作用]
Schweiz Med Wochenschr. 1982 Nov 6;112(45):1585-7.
6
[Anti-arrhythmia agents].[抗心律失常药物]
Med Klin. 1974 May 3;69(18):778-86.
7
[The treatment of cardiac arrhythmias: complexity and schematization].[心律失常的治疗:复杂性与模式化]
Rev Med Suisse Romande. 1973 Jan;93(1):19-36.
8
Limitations of present drug therapy of cardiac arrhythmias--a review.心律失常当前药物治疗的局限性——综述
Postgrad Med J. 1977;53 Suppl 1:12-21.
9
[Medical management of tachycardias (author's transl)].[心动过速的医学管理(作者译)]
Herz. 1979 Aug;4(4):344-58.
10
[Cardiac arrhythmias. I. Pathogenesis and clinical significance].[心律失常。I. 发病机制与临床意义]
Med Klin. 1971 Apr 16;66(16):613-9.

引用本文的文献

1
Ventricular Fibrillation Is a Sign of Life.心室颤动是生命的迹象。
Braz J Cardiovasc Surg. 2023 Oct 6;38(6):e20210428. doi: 10.21470/1678-9741-2021-0428.
2
Survival after prolonged resuscitation with 99 defibrillations due to Torsade De Pointes cardiac electrical storm: a case report.尖端扭转型室性心动过速性电风暴行 99 次除颤后长时间复苏存活 1 例报告
Scand J Trauma Resusc Emerg Med. 2010 Feb 6;18:7. doi: 10.1186/1757-7241-18-7.
3
Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.
评估兔浦肯野纤维试验作为评估人类药物诱发尖端扭转型室性心动过速风险的体外工具。
Drug Saf. 2006;29(3):237-54. doi: 10.2165/00002018-200629030-00007.
4
Drug-induced cardiac arrhythmias: incidence, prevention and management.药物性心律失常:发生率、预防与管理
Drug Saf. 1997 Oct;17(4):265-75. doi: 10.2165/00002018-199717040-00006.
5
Drug-induced torsade de pointes. Incidence, management and prevention.药物性尖端扭转型室性心动过速。发病率、管理与预防。
Drug Saf. 1994 Dec;11(6):463-76. doi: 10.2165/00002018-199411060-00007.
6
Amiodarone: the experience of the past decade.胺碘酮:过去十年的经验
Br Med J (Clin Res Ed). 1983 Dec 3;287(6406):1654-6. doi: 10.1136/bmj.287.6406.1654.
7
QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.QT间期延长药物:其致心律失常风险的机制及临床相关性
Cardiovasc Drugs Ther. 1991 Apr;5(2):515-30. doi: 10.1007/BF03029779.